Disease

Low mortality rate is the biggest advantage of using surfactant replacement therapy to treat neonatal Respiratory Distress Syndrome (RDS) in infants.  Infasurf® is a pure lung surfactant that helps in improving the breathing process of the new-born patient suffering from RDS. p.p1 {margin: 0.0px 0.0px 0.0px 0.0px; font: 11.0px Calibri}